363 related articles for article (PubMed ID: 10925966)
1. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.
Reid BJ; Levine DS; Longton G; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2000 Jul; 95(7):1669-76. PubMed ID: 10925966
[TBL] [Abstract][Full Text] [Related]
2. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
3. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.
Rabinovitch PS; Longton G; Blount PL; Levine DS; Reid BJ
Am J Gastroenterol; 2001 Nov; 96(11):3071-83. PubMed ID: 11721752
[TBL] [Abstract][Full Text] [Related]
4. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.
Reid BJ; Blount PL; Rubin CE; Levine DS; Haggitt RC; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1212-9. PubMed ID: 1551528
[TBL] [Abstract][Full Text] [Related]
5. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.
Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
Gastroenterology; 1987 Jul; 93(1):1-11. PubMed ID: 3582897
[TBL] [Abstract][Full Text] [Related]
6. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
7. Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium.
Levine DS; Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
Gastroenterology; 1989 Feb; 96(2 Pt 1):355-67. PubMed ID: 2910757
[TBL] [Abstract][Full Text] [Related]
8. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
9. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
[TBL] [Abstract][Full Text] [Related]
10. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
11. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
12. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
13. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
14. Is there an advantage to be gained from adding digital image cytometry of brush cytology to a standard biopsy protocol in patients with Barrett's esophagus?
Borovicka J; Schönegg R; Hell M; Kradolfer D; Bauerfeind P; Dorta G; Netzer P; Binek J; Meyenberger C; Fischer JE; Spieler P
Endoscopy; 2009 May; 41(5):409-14. PubMed ID: 19418394
[TBL] [Abstract][Full Text] [Related]
15. Barrett's esophagus, dysplasia, and adenocarcinoma.
Haggitt RC
Hum Pathol; 1994 Oct; 25(10):982-93. PubMed ID: 7927321
[TBL] [Abstract][Full Text] [Related]
16. Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials.
Eisen GM; Montgomery EA; Azumi N; Hartmann DP; Bhargava P; Lippman M; Benjamin SB
Gastrointest Endosc; 1999 Dec; 50(6):814-8. PubMed ID: 10570342
[TBL] [Abstract][Full Text] [Related]
17. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.
Fang M; Lew E; Klein M; Sebo T; Su Y; Goyal R
Am J Gastroenterol; 2004 Oct; 99(10):1887-94. PubMed ID: 15447746
[TBL] [Abstract][Full Text] [Related]
18. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
[TBL] [Abstract][Full Text] [Related]
19. [Flow cytometric analysis of cellular DNA content in Barret's esophagus. A study of 66 cases].
Robaszkiewicz M; Hardy E; Volant A; Nousbaum JB; Cauvin JM; Calament G; Robert FX; Saleun JP; Gouerou H
Gastroenterol Clin Biol; 1991; 15(10):703-10. PubMed ID: 1816011
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
